Oxytocin: research, legal status and who sells it

What it is

Oxytocin is a peptide hormone. Synthetic oxytocin is a licensed prescription medicine in all five markets we track, including Pitocin in the US [1][2][3][4][6].

Research status

Oxytocin’s licensed uses include inducing labor and preventing or treating heavy bleeding after birth (postpartum hemorrhage) [6][8]. A 2019 Cochrane review found that giving oxytocin after vaginal birth may reduce blood loss of 500 mL or more compared with no uterotonic drug (risk ratio 0.51), although the evidence was of low quality [8]. A 2025 Cochrane network meta-analysis of 122 trials and more than 120,000 women confirmed that most uterotonic drugs prevent hemorrhage, ranked combinations of oxytocin with ergometrine or misoprostol highest, and noted that oxytocin is the World Health Organization’s current standard [9].

Claims that intranasal oxytocin changes behavior rest on weak foundations [10]. A 2016 review in Biological Psychiatry concluded that very little intranasal oxytocin appears to reach the cerebrospinal fluid, that blood levels rise to supraphysiological levels with likely effects elsewhere in the body, and that many published measurements used discredited methods [10].

Regulatory status

Oxytocin is approved in the US as Pitocin and as generic oxytocin injection [1], licensed in the UK [2], authorized nationally in most EU countries [3], marketed in Canada [4] and listed in Schedule 4 (prescription-only) in Australia [5]. It is not named on WADA’s 2026 Prohibited List [7].

Quality and testing considerations

Oxytocin sold by peptide vendors as a “research” chemical is not one of the licensed products listed by these regulators [1][2][3][4][6], so its identity, strength and sterility are unknown unless it is independently tested.

Where it’s sold

Oxytocin is a prescription medicine; the tables below track unapproved “research” listings.